Navigation Links
IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
Date:5/16/2013

MOUNTAIN VIEW, Calif., May 16, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has received the final $510,000 cash payment from the February 2012 sale of its aesthetic business unit. The cash was released to IRIDEX from an escrow account set up as part of the transaction.

"The release of the funds from escrow marks the final chapter in the sale of our aesthetics business," said IRIDEX President and CEO Will Moore . "The sale has been a successful transaction. It's great to have the final milestone behind us and have the funds added to our cash balance. We continue to explore new business opportunities and relationships to leverage our cash and technology resources to grow the business."

Moore added that the $510,000 in escrow had previously been reported on the Company's financial statements as part of current assets from discontinued operations.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's strategic growth plans and opportunities. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2013 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
2. IRIDEX Reports 2012 First Quarter Results
3. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
4. IRIDEX Reports 2012 Second Quarter Results
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
7. IRIDEX Reports 2012 Third Quarter Results
8. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
9. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
10. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 2016 Research and Markets has ... Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected ... period 2016-2020. , ,The growing adoption of laser in ... of the market. Lasers are used to treat a ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has qualified to ... at the University of Montana on April 28-May 1. Varize will compete on Saturday ... order to qualify, Varize needed to place top seven all-around in her respective age ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... announces today the open availability of a new CDISC standard, Clinical Trial ... registering clinical trials. This innovative standard will make it possible to build ...
(Date:4/28/2016)... Los Angeles, CA (PRWEB) , ... April 28, 2016 , ... ... section on its website, cosmetictown.com . The forum section was recently revamped and ... about the latest surgical techniques in use across the country. , According to the ...
(Date:4/28/2016)... Beach, FL (PRWEB) , ... April 28, 2016 , ... ... the spring season. Smart pots are frequently used by professional organic farmers and nurseries ... growers to order their supply of fabric pots. Our goal is to offer wholesale ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine ... the emerging field of biomechatronics, technology that marries human physiology with electromechanics. He continues ... He is also the Founder of BionX , a leader in the field ...
Breaking Medicine News(10 mins):